- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01046812
Halitosis Devised Questionnaire Evaluating a New Treatment
Study Overview
Detailed Description
Halitosis is a common symptom which can affect people of all ages. It may decrease self confidence and social interactions. Oral halitosos is the consequence of microbial (mainly Gram negative bacteria) breakdown of food debris, cells, saliva, and blood. The agents that give rise to halitosis include especially the volatile sulphur compounds (VSC), diamines, and short chain fatty acids of which only the VSC can be detected in the clinical setting, making the detection of halitosis often very hard. The most common cause for oral halitosis is poor oral hygiene due to gingivitis or periodontitis. Other causes include bacterial accumulation on the posterior tongue, tonsillitis and others. Dry mouth has been implicated as a potential cause in halitosis.
Due to the lack of quantitative objective measuring to the severity of halitosis and especially in the face of the subjective nature of halitosis as occurs commonly a subjectively measurement is necessary. As no current QOL exists for measurement of halitosis formulation of such a questionnaire can enable a measurement of subjective halitosis with change observed over time or with intervention.
We intend to treat halitosis with a novel approach targeting mouth dryness- when other factors were ruled out by measuring outcome on the halitosis questionnaire.
We will treat mouth dryness with Caphosol- a solution indicated for mouth dryness acting only locally after mouth washing. As this is a supersaturated phosphate solution of a mineral not alien to the body side effects are practically negligible.
Quality of life (QOL) questionnaires (such as SNOT20- sinonasal outcome test) are common in medicine, however no such questionnaire exists for halitosis. We devised a specific QOL questionnaire for halitosis. This questionnaire consists of 20 questions covering functional limitation, physical discomfort, psychological discomfort, physical disability and social disability. The answers will be based on a common scale of 5 answers depending on the severity and ranging from a never bothering symptom to a symptom which as worse as can be. Formulation of this a questionnaire can assist in measuring subjective halitosis with change observed over time or with intervention.
Treating halitosis is a challenge due to the multitude of factors. However, some treatments, mainly in the form of nasal saline irrigation or oral solutions chlorine based or triclosan exist. Mouth dryness, although implicated as a factor, has not been targeted yet. Improving salivary flow may reduce the stasis of saliva thus reducing the concentration of proteins that bacteria dwell on as well as a better degradation of oral food debris.
Caphosol is a topical oral agent of supersaturated calcium phosphate rinse indicated for dry mouth that has been clinically proven to shorten the duration and severity of mucositis and relieve dry mouth when used with fluoride. Caphosol is indicated for dryness of the mouth or throat (hyposalivation, xerostomia), regardless of the cause and regardless of whether the conditions are temporary or permanent. Caphosol is also indicated as an adjunct to standard oral care in treating the mucositis that may be caused by radiation or high dose chemotherapy. It has an extremely high safety profile as these salts are not alien to the body, thus if swallowed accidentally, no adverse effects are expected. No known drug interactions exist.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10019
- New York Head & Neck Institute offices
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients complaining of halitosis
- Patients over 18
- Patients with dry mouth as seen on physical examinations
- Patients that may be suffering from Sjogren's syndrome will be screened by SSB/La blood test.
Exclusion Criteria:
- Patients without any other noted causes contributing to halitosis.
- Patients restricted to a low sodium diet without specific permission from the treating physician.
- Patients not wishing to participate in the study will be asked to fill the questionnaire regardless
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluation of Caphosol in treating Halitosis
Time Frame: 1 month
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Confirmation of QOL questionnaire as tool measuring the burden of halitosis
Time Frame: 1 month
|
1 month
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Porter SR, Scully C. Oral malodour (halitosis). BMJ. 2006 Sep 23;333(7569):632-5. doi: 10.1136/bmj.38954.631968.AE. No abstract available.
- Koshimune S, Awano S, Gohara K, Kurihara E, Ansai T, Takehara T. Low salivary flow and volatile sulfur compounds in mouth air. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Jul;96(1):38-41. doi: 10.1016/s1079-2104(03)00162-8.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SLR 09-141
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Halitosis
-
Hadassah Medical OrganizationCompleted
-
Semmelweis UniversityNot yet recruiting
-
University of North Carolina, Chapel HillColgate PalmoliveCompletedHalitosisUnited States
-
Novozymes A/SCompleted
-
Riyadh Colleges of Dentistry and PharmacyUnknown
-
Cairo UniversityUnknown
-
Universitaire Ziekenhuizen KU LeuvenGaba International AGUnknown
-
Okayama UniversityCompleted
-
Tokyo Medical and Dental UniversityCompleted
Clinical Trials on Caphosol
-
Amphia HospitalErasmus Medical CenterTerminatedSmall Cell Lung Cancer | Non Small Cell Lung CancerNetherlands
-
University of ZurichCompletedAllogeneic Stem Cell TransplantationSwitzerland
-
Nantes University HospitalJazz PharmaceuticalsCompletedHematologic DiseaseFrance
-
Tampere University HospitalTurku University Hospital; Kuopio University HospitalCompleted
-
Impaqtt FoundationMemorial Sloan Kettering Cancer Center; Novartis; Pfizer; Leiden University Medical... and other collaboratorsCompletedRenal Cell Carcinoma | Hepatocellular Carcinoma | Gastrointestinal Stromal Tumors | Oral ComplaintsNetherlands
-
Jazz PharmaceuticalsUnknownOral MucositisUnited States
-
Medical College of WisconsinTerminatedOral MucositisUnited States
-
M.D. Anderson Cancer CenterCompleted
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Chronic Myelomonocytic Leukemia | Juvenile Myelomonocytic Leukemia | Secondary Acute Myeloid Leukemia | Childhood Acute Myeloid Leukemia in Remission | Mucositis | Childhood Acute Lymphoblastic Leukemia in Remission | Childhood Chronic Myelogenous... and other conditionsUnited States, Canada, Australia
-
The University of Texas Health Science Center at...South Texas Veterans Health Care SystemCompleted